ATLANTA – Gliknik Inc., a biopharmaceutical company developing treatments for cancer and autoimmune diseases, has raised $849,000 of a mixed securities offering targeted at $3.9 million, according to a regulatory filing. Six investors contributed thus far.
The company disclosed in June 2010 that Maryland Health Care Product Development Corp. (MHCPDC) had invested an undisclosed amount in the company and said it would invest an additional amount of equity this summer.
The MHCPDC is a non-profit venture investment organization and a supporting organizationof the Tech Council of Maryland.
The company also raised a $3.6 million round in January 2010.
The company evolved from research by professor of Otorhinolarynogology-Head & Neck Surgery at the University of Maryland School of Medicine in Baltimore.
The company was founded by David S. Block, CEO and president, who was previously a senior executive at DuPont Merck and was COO of Celera Genomics. A serial entrepreneur, he also previously founded Ruxton Pharmaceuticals in 2004, a venture-backed startup.
Gliknik disclosed the funding in a filing with the US Securities and Exchange Commission.
The filing names principals as: Dr. David S. Block, president and CEO, and Elizabeth Block; and directors Joseph Klein, III, of Stevenson, Md.-based Gauss Capital Advisors LLC; and Raymond Schinazi, PhD, Professor of Biochemical Pharmacology at Emory University, Atlanta.
BALTIMORE, MD – Gliknik, a biopharmaceutical company developing treatments for cancer and autoimmune diseases, has raised $1.9 million of a targeted $4 million equity round that includes warrants and options, according to a regulatory filing.
